U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07186660) titled 'Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes' on Sept. 12.
Brief Summary: The purpose of this study is to see if the study drug CIR-0602K will improve glucose time-in-range and/or lower total daily insulin dose in people with type 1 diabetes who are using closed-loop automated insulin delivery. Researchers will compare CIR-0602K to a placebo (a look-alike substance that contains no drug) to see if it achieves the investigational endpoints. If the study results show that the drug works to increase time-in-range and lower insulin doses, this will lead to further studies which may then make the drug availabl...